Responses
Regular and young investigator award abstracts
Clinical trials in progress
386 Phase I/Ib first-in-human study of HEK-NIZ985, a recombinant IL-15/IL-15Rα heterodimer, alone and in combination with spartalizumab, in adults with advanced and metastatic solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.